Condition
Hepatitis E Virus Infection
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 2 (1)
P 4 (1)
Trial Status
Completed2
Unknown1
Recruiting1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07525401Not ApplicableNot Yet Recruiting
Comparative Evaluation of Oral Ursodeoxycholic Acid in Reducing Bilirubin Levels Among Patients With Acute Viral Hepatitis
NCT06306196Phase 2RecruitingPrimary
Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
NCT05300425Completed
Seroprevalence of Leptospirosis in Val Müstair, Switzerland
NCT05415345Phase 4Unknown
Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin
NCT02645955CompletedPrimary
Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients
Showing all 5 trials